nodes	percent_of_prediction	percent_of_DWPC	metapath
Ipratropium bromide—Methylphenidate—SLC6A3—Gilles de la Tourette syndrome	0.0478	0.5	CrCbGaD
Ipratropium bromide—Dexmethylphenidate—SLC6A3—Gilles de la Tourette syndrome	0.0478	0.5	CrCbGaD
Ipratropium bromide—CHRM5—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.028	0.0323	CbGpPWpGaD
Ipratropium bromide—CHRM5—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.0238	0.0275	CbGpPWpGaD
Ipratropium bromide—CHRM5—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.0231	0.0267	CbGpPWpGaD
Ipratropium bromide—CHRM5—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.0216	0.0249	CbGpPWpGaD
Ipratropium bromide—CHRM5—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.02	0.0231	CbGpPWpGaD
Ipratropium bromide—CHRM1—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.0197	0.0227	CbGpPWpGaD
Ipratropium bromide—CHRM3—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.0196	0.0227	CbGpPWpGaD
Ipratropium bromide—CHRM5—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.0195	0.0225	CbGpPWpGaD
Ipratropium bromide—CHRM2—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.0194	0.0224	CbGpPWpGaD
Ipratropium bromide—CHRM5—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.0181	0.0209	CbGpPWpGaD
Ipratropium bromide—CHRM1—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.0168	0.0194	CbGpPWpGaD
Ipratropium bromide—CHRM3—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.0167	0.0193	CbGpPWpGaD
Ipratropium bromide—CHRM2—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.0166	0.0191	CbGpPWpGaD
Ipratropium bromide—CHRM1—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.0163	0.0188	CbGpPWpGaD
Ipratropium bromide—CHRM3—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.0162	0.0188	CbGpPWpGaD
Ipratropium bromide—CHRM2—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.0161	0.0186	CbGpPWpGaD
Ipratropium bromide—SLC22A4—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC6A3—Gilles de la Tourette syndrome	0.016	0.0184	CbGpPWpGaD
Ipratropium bromide—CHRM1—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.0152	0.0175	CbGpPWpGaD
Ipratropium bromide—CHRM3—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.0151	0.0175	CbGpPWpGaD
Ipratropium bromide—CHRM5—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.0151	0.0174	CbGpPWpGaD
Ipratropium bromide—CHRM2—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.015	0.0173	CbGpPWpGaD
Ipratropium bromide—CHRM1—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.0141	0.0163	CbGpPWpGaD
Ipratropium bromide—CHRM3—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.0141	0.0162	CbGpPWpGaD
Ipratropium bromide—CHRM2—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.0139	0.0161	CbGpPWpGaD
Ipratropium bromide—CHRM1—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.0137	0.0158	CbGpPWpGaD
Ipratropium bromide—CHRM3—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.0137	0.0158	CbGpPWpGaD
Ipratropium bromide—CHRM2—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.0135	0.0156	CbGpPWpGaD
Ipratropium bromide—CHRM1—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.0128	0.0147	CbGpPWpGaD
Ipratropium bromide—CHRM3—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.0127	0.0147	CbGpPWpGaD
Ipratropium bromide—CHRM5—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.0127	0.0147	CbGpPWpGaD
Ipratropium bromide—CHRM2—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.0126	0.0145	CbGpPWpGaD
Ipratropium bromide—SLC22A5—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC6A3—Gilles de la Tourette syndrome	0.012	0.0139	CbGpPWpGaD
Ipratropium bromide—CHRM1—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.0106	0.0123	CbGpPWpGaD
Ipratropium bromide—CHRM3—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.0106	0.0122	CbGpPWpGaD
Ipratropium bromide—CHRM2—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.0105	0.0121	CbGpPWpGaD
Ipratropium bromide—CHRM1—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.00894	0.0103	CbGpPWpGaD
Ipratropium bromide—CHRM3—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.00891	0.0103	CbGpPWpGaD
Ipratropium bromide—CHRM2—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.00882	0.0102	CbGpPWpGaD
Ipratropium bromide—CHRM3—GPCRs, Other—DRD3—Gilles de la Tourette syndrome	0.00743	0.00858	CbGpPWpGaD
Ipratropium bromide—CHRM2—GPCRs, Other—DRD3—Gilles de la Tourette syndrome	0.00736	0.0085	CbGpPWpGaD
Ipratropium bromide—SLC22A4—SLC-mediated transmembrane transport—SLC6A3—Gilles de la Tourette syndrome	0.00725	0.00837	CbGpPWpGaD
Ipratropium bromide—CHRM3—GPCRs, Other—DRD4—Gilles de la Tourette syndrome	0.00722	0.00833	CbGpPWpGaD
Ipratropium bromide—CHRM2—GPCRs, Other—DRD4—Gilles de la Tourette syndrome	0.00715	0.00825	CbGpPWpGaD
Ipratropium bromide—SLC22A5—SLC-mediated transmembrane transport—SLC6A3—Gilles de la Tourette syndrome	0.00545	0.00629	CbGpPWpGaD
Ipratropium bromide—CHRM3—GPCRs, Other—HTR2A—Gilles de la Tourette syndrome	0.00471	0.00544	CbGpPWpGaD
Ipratropium bromide—CHRM2—GPCRs, Other—HTR2A—Gilles de la Tourette syndrome	0.00466	0.00538	CbGpPWpGaD
Ipratropium bromide—CHRM5—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.0046	0.00531	CbGpPWpGaD
Ipratropium bromide—CHRM5—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.00447	0.00516	CbGpPWpGaD
Ipratropium bromide—CHRM5—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.00416	0.0048	CbGpPWpGaD
Ipratropium bromide—CHRM1—Circadian rythm related genes—DRD3—Gilles de la Tourette syndrome	0.00396	0.00457	CbGpPWpGaD
Ipratropium bromide—CHRM5—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.00394	0.00455	CbGpPWpGaD
Ipratropium bromide—CHRM1—Circadian rythm related genes—DRD4—Gilles de la Tourette syndrome	0.00384	0.00443	CbGpPWpGaD
Ipratropium bromide—CHRM5—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.00383	0.00442	CbGpPWpGaD
Ipratropium bromide—CHRM5—G alpha (q) signalling events—HTR2A—Gilles de la Tourette syndrome	0.00377	0.00435	CbGpPWpGaD
Ipratropium bromide—SLC22A4—Transmembrane transport of small molecules—SLC6A3—Gilles de la Tourette syndrome	0.00369	0.00426	CbGpPWpGaD
Ipratropium bromide—CHRM1—Circadian rythm related genes—DRD2—Gilles de la Tourette syndrome	0.00358	0.00413	CbGpPWpGaD
Ipratropium bromide—CHRM5—nervous system—Gilles de la Tourette syndrome	0.00357	0.0933	CbGeAlD
Ipratropium bromide—CHRM5—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.00357	0.00412	CbGpPWpGaD
Ipratropium bromide—CHRM2—G alpha (i) signalling events—DRD3—Gilles de la Tourette syndrome	0.00345	0.00398	CbGpPWpGaD
Ipratropium bromide—CHRM5—central nervous system—Gilles de la Tourette syndrome	0.00343	0.0898	CbGeAlD
Ipratropium bromide—CHRM5—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—Gilles de la Tourette syndrome	0.00337	0.00389	CbGpPWpGaD
Ipratropium bromide—CHRM2—G alpha (i) signalling events—DRD4—Gilles de la Tourette syndrome	0.00335	0.00386	CbGpPWpGaD
Ipratropium bromide—CHRM1—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.00324	0.00374	CbGpPWpGaD
Ipratropium bromide—CHRM3—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.00323	0.00373	CbGpPWpGaD
Ipratropium bromide—CHRM2—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.0032	0.00369	CbGpPWpGaD
Ipratropium bromide—CHRM1—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.00315	0.00363	CbGpPWpGaD
Ipratropium bromide—CHRM3—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.00314	0.00362	CbGpPWpGaD
Ipratropium bromide—CHRM2—G alpha (i) signalling events—DRD2—Gilles de la Tourette syndrome	0.00312	0.0036	CbGpPWpGaD
Ipratropium bromide—CHRM2—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.0031	0.00358	CbGpPWpGaD
Ipratropium bromide—CHRM2—SIDS Susceptibility Pathways—HTR2A—Gilles de la Tourette syndrome	0.00303	0.0035	CbGpPWpGaD
Ipratropium bromide—CHRM5—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.003	0.00347	CbGpPWpGaD
Ipratropium bromide—CHRM1—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.00293	0.00338	CbGpPWpGaD
Ipratropium bromide—CHRM3—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.00292	0.00337	CbGpPWpGaD
Ipratropium bromide—CHRM5—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.00291	0.00337	CbGpPWpGaD
Ipratropium bromide—CHRM5—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.00291	0.00336	CbGpPWpGaD
Ipratropium bromide—CHRM2—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.00289	0.00334	CbGpPWpGaD
Ipratropium bromide—CHRM1—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.00278	0.0032	CbGpPWpGaD
Ipratropium bromide—SLC22A5—Transmembrane transport of small molecules—SLC6A3—Gilles de la Tourette syndrome	0.00277	0.0032	CbGpPWpGaD
Ipratropium bromide—CHRM3—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.00277	0.00319	CbGpPWpGaD
Ipratropium bromide—CHRM2—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.00274	0.00316	CbGpPWpGaD
Ipratropium bromide—CHRM5—brain—Gilles de la Tourette syndrome	0.00273	0.0713	CbGeAlD
Ipratropium bromide—CHRM5—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.00272	0.00313	CbGpPWpGaD
Ipratropium bromide—CHRM1—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.00269	0.00311	CbGpPWpGaD
Ipratropium bromide—CHRM3—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.00269	0.0031	CbGpPWpGaD
Ipratropium bromide—CHRM2—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.00266	0.00307	CbGpPWpGaD
Ipratropium bromide—CHRM1—G alpha (q) signalling events—HTR2A—Gilles de la Tourette syndrome	0.00265	0.00307	CbGpPWpGaD
Ipratropium bromide—CHRM3—G alpha (q) signalling events—HTR2A—Gilles de la Tourette syndrome	0.00265	0.00306	CbGpPWpGaD
Ipratropium bromide—CHRM1—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.00251	0.0029	CbGpPWpGaD
Ipratropium bromide—CHRM3—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.0025	0.00289	CbGpPWpGaD
Ipratropium bromide—CHRM5—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.0025	0.00288	CbGpPWpGaD
Ipratropium bromide—CHRM2—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.00248	0.00286	CbGpPWpGaD
Ipratropium bromide—CHRM2—nervous system—Gilles de la Tourette syndrome	0.00245	0.064	CbGeAlD
Ipratropium bromide—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—Gilles de la Tourette syndrome	0.00237	0.00274	CbGpPWpGaD
Ipratropium bromide—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—Gilles de la Tourette syndrome	0.00237	0.00273	CbGpPWpGaD
Ipratropium bromide—CHRM2—central nervous system—Gilles de la Tourette syndrome	0.00236	0.0616	CbGeAlD
Ipratropium bromide—CHRM1—nervous system—Gilles de la Tourette syndrome	0.00223	0.0583	CbGeAlD
Ipratropium bromide—CHRM1—central nervous system—Gilles de la Tourette syndrome	0.00215	0.0561	CbGeAlD
Ipratropium bromide—CHRM1—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.00211	0.00244	CbGpPWpGaD
Ipratropium bromide—CHRM3—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.00211	0.00243	CbGpPWpGaD
Ipratropium bromide—CHRM2—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.00209	0.00241	CbGpPWpGaD
Ipratropium bromide—CHRM1—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.00205	0.00237	CbGpPWpGaD
Ipratropium bromide—CHRM1—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.00205	0.00237	CbGpPWpGaD
Ipratropium bromide—CHRM3—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.00205	0.00236	CbGpPWpGaD
Ipratropium bromide—CHRM3—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.00205	0.00236	CbGpPWpGaD
Ipratropium bromide—SLC22A5—midbrain—Gilles de la Tourette syndrome	0.00203	0.0532	CbGeAlD
Ipratropium bromide—CHRM2—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.00203	0.00234	CbGpPWpGaD
Ipratropium bromide—CHRM2—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.00203	0.00234	CbGpPWpGaD
Ipratropium bromide—CHRM3—Metabolism—HDC—Gilles de la Tourette syndrome	0.00202	0.00233	CbGpPWpGaD
Ipratropium bromide—CHRM3—nervous system—Gilles de la Tourette syndrome	0.00199	0.0521	CbGeAlD
Ipratropium bromide—SLC22A4—brain—Gilles de la Tourette syndrome	0.00193	0.0505	CbGeAlD
Ipratropium bromide—CHRM3—central nervous system—Gilles de la Tourette syndrome	0.00192	0.0502	CbGeAlD
Ipratropium bromide—CHRM1—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.00191	0.00221	CbGpPWpGaD
Ipratropium bromide—CHRM3—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.00191	0.0022	CbGpPWpGaD
Ipratropium bromide—CHRM5—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	0.0019	0.0022	CbGpPWpGaD
Ipratropium bromide—CHRM2—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.00189	0.00218	CbGpPWpGaD
Ipratropium bromide—CHRM2—brain—Gilles de la Tourette syndrome	0.00187	0.0489	CbGeAlD
Ipratropium bromide—CHRM1—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.00176	0.00203	CbGpPWpGaD
Ipratropium bromide—CHRM3—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.00175	0.00202	CbGpPWpGaD
Ipratropium bromide—CHRM2—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.00174	0.002	CbGpPWpGaD
Ipratropium bromide—CHRM1—brain—Gilles de la Tourette syndrome	0.0017	0.0445	CbGeAlD
Ipratropium bromide—CHRM5—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.0017	0.00196	CbGpPWpGaD
Ipratropium bromide—CHRM5—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.00165	0.0019	CbGpPWpGaD
Ipratropium bromide—CHRM5—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.00154	0.00178	CbGpPWpGaD
Ipratropium bromide—CHRM5—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.00153	0.00177	CbGpPWpGaD
Ipratropium bromide—CHRM3—brain—Gilles de la Tourette syndrome	0.00152	0.0399	CbGeAlD
Ipratropium bromide—CHRM5—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.0015	0.00173	CbGpPWpGaD
Ipratropium bromide—CHRM5—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.00139	0.00161	CbGpPWpGaD
Ipratropium bromide—CHRM1—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	0.00134	0.00155	CbGpPWpGaD
Ipratropium bromide—CHRM3—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	0.00133	0.00154	CbGpPWpGaD
Ipratropium bromide—CHRM2—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	0.00132	0.00153	CbGpPWpGaD
Ipratropium bromide—SLC22A5—brain—Gilles de la Tourette syndrome	0.00128	0.0334	CbGeAlD
Ipratropium bromide—CYP2D6—Metabolism—HDC—Gilles de la Tourette syndrome	0.00121	0.00139	CbGpPWpGaD
Ipratropium bromide—CHRM1—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.00119	0.00138	CbGpPWpGaD
Ipratropium bromide—CHRM3—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.00119	0.00137	CbGpPWpGaD
Ipratropium bromide—CHRM2—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.00118	0.00136	CbGpPWpGaD
Ipratropium bromide—CHRM1—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.00116	0.00134	CbGpPWpGaD
Ipratropium bromide—CHRM3—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.00116	0.00133	CbGpPWpGaD
Ipratropium bromide—CHRM2—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.00114	0.00132	CbGpPWpGaD
Ipratropium bromide—CYP3A4—nervous system—Gilles de la Tourette syndrome	0.0011	0.0287	CbGeAlD
Ipratropium bromide—CHRM1—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.00108	0.00125	CbGpPWpGaD
Ipratropium bromide—CHRM3—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.00108	0.00125	CbGpPWpGaD
Ipratropium bromide—CHRM1—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.00108	0.00125	CbGpPWpGaD
Ipratropium bromide—CYP2D6—nervous system—Gilles de la Tourette syndrome	0.00108	0.0282	CbGeAlD
Ipratropium bromide—CHRM3—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.00108	0.00124	CbGpPWpGaD
Ipratropium bromide—CHRM5—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	0.00107	0.00124	CbGpPWpGaD
Ipratropium bromide—CHRM2—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.00107	0.00124	CbGpPWpGaD
Ipratropium bromide—CHRM2—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.00107	0.00123	CbGpPWpGaD
Ipratropium bromide—CYP3A4—central nervous system—Gilles de la Tourette syndrome	0.00106	0.0276	CbGeAlD
Ipratropium bromide—CHRM1—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.00105	0.00122	CbGpPWpGaD
Ipratropium bromide—CHRM3—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.00105	0.00121	CbGpPWpGaD
Ipratropium bromide—CHRM2—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.00104	0.0012	CbGpPWpGaD
Ipratropium bromide—CYP2D6—central nervous system—Gilles de la Tourette syndrome	0.00104	0.0271	CbGeAlD
Ipratropium bromide—CHRM1—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.000981	0.00113	CbGpPWpGaD
Ipratropium bromide—CHRM3—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.000978	0.00113	CbGpPWpGaD
Ipratropium bromide—CHRM5—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	0.000976	0.00113	CbGpPWpGaD
Ipratropium bromide—CHRM2—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.000968	0.00112	CbGpPWpGaD
Ipratropium bromide—CHRM5—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.00091	0.00105	CbGpPWpGaD
Ipratropium bromide—CHRM5—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.000884	0.00102	CbGpPWpGaD
Ipratropium bromide—CYP2D6—brain—Gilles de la Tourette syndrome	0.000824	0.0216	CbGeAlD
Ipratropium bromide—CHRM5—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.000823	0.00095	CbGpPWpGaD
Ipratropium bromide—CYP3A4—Metabolism—HDC—Gilles de la Tourette syndrome	0.00079	0.000912	CbGpPWpGaD
Ipratropium bromide—CHRM1—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	0.000757	0.000874	CbGpPWpGaD
Ipratropium bromide—CHRM3—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	0.000754	0.000871	CbGpPWpGaD
Ipratropium bromide—CHRM2—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	0.000747	0.000862	CbGpPWpGaD
Ipratropium bromide—CHRM1—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	0.000687	0.000793	CbGpPWpGaD
Ipratropium bromide—CHRM3—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	0.000685	0.000791	CbGpPWpGaD
Ipratropium bromide—CHRM2—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	0.000678	0.000783	CbGpPWpGaD
Ipratropium bromide—CHRM1—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.000641	0.00074	CbGpPWpGaD
Ipratropium bromide—CHRM3—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.000639	0.000738	CbGpPWpGaD
Ipratropium bromide—CHRM2—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.000633	0.00073	CbGpPWpGaD
Ipratropium bromide—CHRM1—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.000622	0.000718	CbGpPWpGaD
Ipratropium bromide—CHRM3—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.00062	0.000716	CbGpPWpGaD
Ipratropium bromide—CHRM2—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.000614	0.000709	CbGpPWpGaD
Ipratropium bromide—CHRM1—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.00058	0.000669	CbGpPWpGaD
Ipratropium bromide—CHRM3—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.000578	0.000667	CbGpPWpGaD
Ipratropium bromide—CHRM5—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.000576	0.000666	CbGpPWpGaD
Ipratropium bromide—CHRM2—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.000572	0.00066	CbGpPWpGaD
Ipratropium bromide—CHRM1—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.000406	0.000469	CbGpPWpGaD
Ipratropium bromide—CHRM3—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.000405	0.000467	CbGpPWpGaD
Ipratropium bromide—CHRM2—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.000401	0.000463	CbGpPWpGaD
